[go: up one dir, main page]

BRPI0512569A - métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humano - Google Patents

métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humano

Info

Publication number
BRPI0512569A
BRPI0512569A BRPI0512569-3A BRPI0512569A BRPI0512569A BR PI0512569 A BRPI0512569 A BR PI0512569A BR PI0512569 A BRPI0512569 A BR PI0512569A BR PI0512569 A BRPI0512569 A BR PI0512569A
Authority
BR
Brazil
Prior art keywords
eye
mammal
reduce
formation
methods
Prior art date
Application number
BRPI0512569-3A
Other languages
English (en)
Inventor
Kenneth Widder
Jay Lichter
Nathan L Mata
Original Assignee
Sirion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34981643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0512569(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirion Therapeutics Inc filed Critical Sirion Therapeutics Inc
Publication of BRPI0512569A publication Critical patent/BRPI0512569A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MéTODOS PARA REDUZIR A FORMAçãO DE N-RETINILIDENO-N-RETINILETANOLAMINA NO OLHO DE UM MAMìFERO, PARA REDUZIR A FORMAçãO DE LIPOFUSCINA NO OLHO DE UM MAMìFERO, PARA TRATAR DEGENERAçãO MACULAR RELACIONADA COM A IDADE NA FORMA SECA NO OLHO DE UM MAMìFERO E PARA REDUZIR ATROFIA GEOGRáFICA NO OLHO DE UM HUMANO Compostos que causam cegueira á noite reversível podem ser usados para tratar condições oftálmicas associadas com a sobreprodução de produtos de rejeito que se acumulam durante o curso do ciclo visual. São descritos métodos e composições usando tais compostos e seus derivados para tratar, por exemplo, as degenerações e distrofias maculares ou para aliviar sintomas associados com tais condições oftálmicas. Tais compostos e seus derivados podem ser usados como terapia de agente único ou em combinação com outros agentes ou terapias.
BRPI0512569-3A 2004-06-23 2005-06-06 métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humano BRPI0512569A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58229304P 2004-06-23 2004-06-23
US62969504P 2004-11-19 2004-11-19
US66090405P 2005-03-11 2005-03-11
US67240505P 2005-04-18 2005-04-18
PCT/US2005/020080 WO2006007314A1 (en) 2004-06-23 2005-06-06 Methods and compositions for treating ophthalmic conditions with retinyl derivatives

Publications (1)

Publication Number Publication Date
BRPI0512569A true BRPI0512569A (pt) 2008-03-25

Family

ID=34981643

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512569-3A BRPI0512569A (pt) 2004-06-23 2005-06-06 métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humano

Country Status (26)

Country Link
US (3) US8314152B2 (pt)
EP (3) EP2277516A1 (pt)
JP (1) JP4855396B2 (pt)
KR (1) KR100862930B1 (pt)
AR (1) AR049929A1 (pt)
AT (1) ATE404188T1 (pt)
AU (1) AU2005262558B8 (pt)
BR (1) BRPI0512569A (pt)
CA (1) CA2569691C (pt)
CY (1) CY1110435T1 (pt)
DE (1) DE602005008970D1 (pt)
DK (1) DK1768657T3 (pt)
EA (1) EA011864B1 (pt)
ES (1) ES2313368T3 (pt)
GE (1) GEP20084520B (pt)
IL (1) IL179872A (pt)
LV (1) LV13564B (pt)
MX (1) MXPA06014978A (pt)
NO (1) NO20070408L (pt)
NZ (1) NZ551955A (pt)
PL (1) PL1768657T3 (pt)
PT (1) PT1768657E (pt)
SG (1) SG140607A1 (pt)
SI (1) SI1768657T1 (pt)
TW (1) TWI396532B (pt)
WO (1) WO2006007314A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242704A1 (en) 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
RU2006133300A (ru) 2004-02-17 2008-03-27 Президент Энд Феллоуз Оф Гарвард Колледж (Us) Управление течением офтальмологических расстройств, включая дегенерацию желтого пятна
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
EP2397131B1 (en) 2004-06-18 2019-09-11 University of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
GEP20084520B (en) 2004-06-23 2008-10-27 Sirion Therapeutics Inc Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
CA2575265A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat ophthalmic disorders
US8293253B2 (en) * 2004-10-28 2012-10-23 Idexx Laboratories, Inc. Compositions for controlled delivery of pharmaceutically active compounds
CA2584396A1 (en) * 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
CN102240278A (zh) * 2004-12-08 2011-11-16 矫正诊疗公司 治疗与视黄醇有关的疾病的方法、分析和组合物
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
US7754679B2 (en) * 2005-11-16 2010-07-13 Idexx Laboratories, Inc. Pharmaceutical compositions for the administration of aptamers
US8114440B2 (en) * 2005-11-16 2012-02-14 Idexx Laboratories Inc. Pharmaceutical compositions for the administration of aptamers
EP2037951A2 (en) * 2006-06-22 2009-03-25 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions via modulation of megalin activity
WO2008013983A2 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
CA2657164A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic light toxicity
AU2007277033A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic disease
US8828960B2 (en) * 2007-07-17 2014-09-09 Idexx Laboratories, Inc. Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
CA2714530C (en) 2008-02-11 2018-09-25 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
WO2009114136A2 (en) * 2008-03-12 2009-09-17 Albert Einstein College Of Medicine Of Yeshiva University Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents
JP5491502B2 (ja) * 2008-07-14 2014-05-14 オトノミ―，インク． 制御放出アポトーシス調節化合物および耳の障害の処置のための方法
US20120108665A1 (en) * 2009-05-04 2012-05-03 Revision Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions
IN2012DN00352A (pt) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
US20120178806A1 (en) 2009-09-15 2012-07-12 Qlt Inc. Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
KR20180043846A (ko) 2010-04-19 2018-04-30 노벨리언 테라퓨틱스 인코포레이티드 내인성 레티노이드 결핍과 연관된 시각 장애의 치료 또는 완화를 위한 치료 요법 및 방법
AU2012346214B2 (en) 2011-11-30 2017-09-14 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
PT2797601T (pt) * 2012-02-10 2018-06-27 Taiwan Liposome Co Ltd Composições farmacêuticas para reduzir complicações de esteroide ocular
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US9011845B2 (en) 2012-06-26 2015-04-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for treatment of inflammatory and infectious viral diseases
WO2014003850A2 (en) 2012-06-26 2014-01-03 Timothy Paul Foster Methods for treatment of ocular diseases
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10092393B2 (en) 2013-03-14 2018-10-09 Allotex, Inc. Corneal implant systems and methods
US10471118B2 (en) * 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
CN107108506B (zh) 2014-10-24 2022-06-21 武田药品工业株式会社 杂环化合物
PL3233174T3 (pl) * 2014-12-19 2021-08-30 Kemin Industries, Inc. Wewnątrzgałkowe dostarczanie bioaktywnych cząsteczek za pomocą jontoforezy
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
RU2718065C2 (ru) * 2016-02-15 2020-03-30 Кемин Индастриз, Инк. Положительно заряженные липосомы в качестве липофильных молекул-носителей
US11395853B2 (en) * 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
CA3084568A1 (en) * 2016-12-05 2018-06-14 The Jackson Laboratory Fat droplets in retina and optic nerve as a diagnostic marker for neurodegeneration and glaucoma in humans
ES2999266T3 (en) * 2017-07-04 2025-02-25 Daiichi Sankyo Co Ltd Drug for retinal degenerative disease associated with photoreceptor degeneration
BR112021022270A2 (pt) * 2019-05-06 2022-01-11 Univ California Materiais e métodos para tratar degeneração macular relacionada à idade
FR3105790B1 (fr) * 2019-12-26 2022-01-14 Biophytis Composés chimiques ciblant l’œil et leur utilisation dans le traitement de maladies oculaires

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190594A (en) 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
US4665098A (en) 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US4673044A (en) * 1985-08-02 1987-06-16 Eastman Christensen Co. Earth boring bit for soft to hard formations
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4682663A (en) * 1986-02-18 1987-07-28 Reed Tool Company Mounting means for cutting elements in drag type rotary drill bit
US4743400A (en) 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
AU6141490A (en) 1989-07-28 1991-03-11 Sloan-Kettering Institute For Cancer Research Growth factors containing vitamin a or other retinoids and uses thereof
US5814612A (en) 1991-04-09 1998-09-29 Sloan-Kettering Institute For Cancer Research Retinol derivatives and uses thereof
US6992108B1 (en) 1991-12-18 2006-01-31 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US6050354A (en) * 1992-01-31 2000-04-18 Baker Hughes Incorporated Rolling cutter bit with shear cutting gage
US5314909A (en) 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
US5399757A (en) 1993-07-20 1995-03-21 Ortho Pharmaceutical Corporation Process for the preparation of N-(4-hydroxyphenyl)-retinamide
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
US5702357A (en) * 1995-06-07 1997-12-30 Cobe Laboratories, Inc. Extracorporeal blood processing methods and apparatus
US5706906A (en) * 1996-02-15 1998-01-13 Baker Hughes Incorporated Superabrasive cutting element with enhanced durability and increased wear life, and apparatus so equipped
US5758733A (en) * 1996-04-17 1998-06-02 Baker Hughes Incorporated Earth-boring bit with super-hard cutting elements
US5846220A (en) 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US6034211A (en) 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
GB9621217D0 (en) * 1996-10-11 1996-11-27 Camco Drilling Group Ltd Improvements in or relating to preform cutting elements for rotary drill bits
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
US5955305A (en) 1997-04-28 1999-09-21 Incyte Pharmaceuticals, Inc. Human retinoid binding protein
US5776915A (en) 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
CN1275911A (zh) 1997-08-15 2000-12-06 杜克大学 一种预防或治疗雌激素依赖性疾病及失调的方法
EP1083896A4 (en) 1998-05-11 2002-09-11 Endowment For Res In Human Bio USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
CO5200852A1 (es) 1999-09-14 2002-09-27 Lilly Co Eli Moduladores rxr con mejorado perfil farmacologico ceptores x de los retinoides
AU3082901A (en) 1999-11-23 2001-06-04 Gerhart Graupner Modulation of signal transduction
US20020031539A1 (en) 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
WO2002032413A2 (en) 2000-10-17 2002-04-25 Board Of Regents, The University Of Texas System A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes
US6408958B1 (en) * 2000-10-23 2002-06-25 Baker Hughes Incorporated Superabrasive cutting assemblies including cutters of varying orientations and drill bits so equipped
ATE414511T1 (de) 2000-12-05 2008-12-15 Los Angeles Childrens Hospital Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung
US20030032078A1 (en) 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
EP1390343B1 (en) 2001-05-29 2009-10-14 Chebigen Co., Ltd. Novel retinoid derivatives and an anti-cancer pharmaceutical composition comprising said compounds
EP1404672B1 (en) 2001-06-22 2006-01-18 Merck & Co., Inc. Tyrosine kinase inhibitors
US6696606B2 (en) 2001-07-06 2004-02-24 The Ohio State University Research Foundation Solid phase synthesis of arylretinamides
WO2003007944A1 (en) 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US20030229062A1 (en) 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US20040014131A1 (en) 2002-07-09 2004-01-22 Pfizer Inc. Assay methods
US7595430B2 (en) 2002-10-30 2009-09-29 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20060151574A1 (en) 2002-11-29 2006-07-13 Gpc Biotech Ag Formulations useful against hepatitis C virus infections
SI21392A (sl) 2002-12-24 2004-06-30 Vinko Kunc Postopek za avtomatsko nastavitev ojačenja izpraševalnikovega sprejemnika v brezkontaktnem identifikacijskem sistemu
MXPA05008138A (es) 2003-01-31 2006-02-17 Los Angeles Childrens Hospital Composiciones orales de fenretinida que tienen biodisponibilidad incrementada y metodos de uso de las mismas.
FI20030426A7 (fi) 2003-03-24 2004-09-25 Jaervinen Tomi Syklodekstriinikompleksit
US7178609B2 (en) * 2003-08-19 2007-02-20 Baker Hughes Incorporated Window mill and drill bit
JP4869942B2 (ja) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
WO2005077176A1 (en) 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
RU2006133300A (ru) * 2004-02-17 2008-03-27 Президент Энд Феллоуз Оф Гарвард Колледж (Us) Управление течением офтальмологических расстройств, включая дегенерацию желтого пятна
EP1727529B1 (en) 2004-03-17 2016-03-02 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
EP2397131B1 (en) 2004-06-18 2019-09-11 University of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
GEP20084520B (en) 2004-06-23 2008-10-27 Sirion Therapeutics Inc Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
US7286860B2 (en) 2004-07-23 2007-10-23 Dyna Llc Systems and methods for a comfortable wireless communication device
CA2575265A1 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat ophthalmic disorders
CA2584396A1 (en) 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
CN102240278A (zh) 2004-12-08 2011-11-16 矫正诊疗公司 治疗与视黄醇有关的疾病的方法、分析和组合物
UA81382C2 (en) 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding

Also Published As

Publication number Publication date
AU2005262558B2 (en) 2008-03-20
IL179872A (en) 2013-01-31
EA200700109A1 (ru) 2007-10-26
JP2008504257A (ja) 2008-02-14
NO20070408L (no) 2007-03-20
SG140607A1 (en) 2008-03-28
EP2277516A1 (en) 2011-01-26
EP2025336A1 (en) 2009-02-18
CY1110435T1 (el) 2015-04-29
US8314152B2 (en) 2012-11-20
CA2569691C (en) 2010-08-17
NZ551955A (en) 2010-08-27
WO2006007314A1 (en) 2006-01-19
AU2005262558B8 (en) 2008-04-10
DK1768657T3 (da) 2008-12-01
CA2569691A1 (en) 2006-01-19
MXPA06014978A (es) 2007-04-25
ES2313368T3 (es) 2009-03-01
DE602005008970D1 (de) 2008-09-25
US20100298443A1 (en) 2010-11-25
LV13564B (en) 2008-02-20
EA011864B1 (ru) 2009-06-30
GEP20084520B (en) 2008-10-27
US20060167088A1 (en) 2006-07-27
TW200612891A (en) 2006-05-01
KR100862930B1 (ko) 2008-10-13
KR20070074541A (ko) 2007-07-12
ATE404188T1 (de) 2008-08-15
US8410168B2 (en) 2013-04-02
SI1768657T1 (sl) 2009-02-28
PT1768657E (pt) 2008-11-25
HK1107671A1 (en) 2008-04-11
EP1768657A1 (en) 2007-04-04
JP4855396B2 (ja) 2012-01-18
PL1768657T3 (pl) 2009-01-30
AU2005262558A1 (en) 2006-01-19
US20110294891A1 (en) 2011-12-01
TWI396532B (zh) 2013-05-21
AR049929A1 (es) 2006-09-13
EP1768657B1 (en) 2008-08-13
IL179872A0 (en) 2007-05-15

Similar Documents

Publication Publication Date Title
BRPI0512569A (pt) métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humano
WO2007150046A3 (en) Methods and compositions for treating ophthalmic conditions via modulation of megalin activity
BRPI0514829A (pt) domìnios e epitopos da proteìna meningocócica nmb1870
PE20080053A1 (es) Composiciones oftalmicas de alcaftadina
WO2006033734A3 (en) Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
TW200727894A (en) Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation
BRPI0415699A (pt) uso de oligossacarìdeo ácido e de oligossacarìdeo neutro, e, composições alimentìcia e lìquida
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
BR0317033A (pt) Vitreólise farmacológica
MXPA06014470A (es) Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas.
WO2009061447A3 (en) Use of umbilical cord blood in the treatment of premature birth complications
MXPA05008570A (es) Metodos para la prevencion y tratamiento de danos tisulares asociados con una lesion por isquemia-reperfusion.
ATE265856T1 (de) Augenlösung mit tetracyclin für behandlung von trockenen augen
WO2004019884A3 (en) Agents and methods for enhancing bone formation
CR20210544A (es) DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
IN2015DN02751A (pt)
MXPA04000839A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO2008013986A3 (en) Compositions and methods for treating or preventing ophthalmic light toxicity
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
ATE214613T1 (de) Zusammensetzungen, die einen guggul-extrakt mit phosphatsalzen enthalten
BRPI0415571A (pt) composições de limpeza

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: REVISION THERAPEUTICS, INC (US)

Free format text: TRANSFERIDO DE: SIRION THERAPEUTICS, INC.

B25G Requested change of headquarter approved

Owner name: REVISION THERAPEUTICS, INC (US)

Free format text: SEDE ALTERADA CONFORME PET NO 020100070609 - RJ DE 30/07/2010.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: SIRION THERAPEUTICS, INC. (US)

Free format text: ANULADA A TRANSFERENCIA PUBLICADA NA RPI 2103 DE 26/04/2011, POR TER SIDO INDEVIDA

B25A Requested transfer of rights approved

Owner name: REVISION THERAPEUTICS, INC. (US)

Free format text: TRANSFERIDO DE: SIRION THERAPEUTICS, INC.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2310 DE 14-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25H Request for change of headquarter rejected

Owner name: REVISION THERAPEUTICS, INC. (US)